Most cited papers from Klinik Schillerhöhe

Klinik Schillerhöhe

What are the most cited papers from Klinik Schillerhöhe?

The most cited paper from Klinik Schillerhöhe is "Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial" (Howard West, Michael McCleod, Maen Hussein et al., 2019), with 1,711 citations. Next come "Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort" (748) and "Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases" (267).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 41 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology	20 May 2019	1,711
2	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Sigbjørn Smeland et al. · European Journal of Cancer Open access	27 Jan 2019	748
3	Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases Godehard Friedel · European Journal of Cardio-Thoracic Surgery Open access	Sep 2002	267
4	Pulmonary Metastasectomy: A Survey of Current Practice Amongst Members of the European Society of Thoracic Surgeons Eveline Internullo, Stephen D. Cassivi, Dirk E. Van Raemdonck et al. · Journal of Thoracic Oncology Open access	Nov 2008	228
5	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry Marius M. Hoeper et al. · The Journal of Heart and Lung Transplantation Open access	30 Sep 2020	215
6	Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon Rainer Ehmann, E. Boedeker, U Friedrich et al. · European Respiratory Journal Open access	18 Aug 2011	211
7	Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice Thomas Meier, H.-P. Eulenbruch, Peter Wrighton-Smith et al. · European Journal of Clinical Microbiology & Infectious Diseases	Aug 2005	208
8	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Jürgen Behr et al. · European Respiratory Journal Open access	7 May 2020	194
9	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study Luca Valerio et al. · European Heart Journal Open access	14 Apr 2022	190
10	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407 Steven Francis Powell, Delvys Rodríguez‐Abreu, Corey Jay Langer et al. · Journal of Thoracic Oncology Open access	12 Jul 2021	188
11	Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease Patrick Huppmann, Bernd Sczepanski, Martina Boensch et al. · European Respiratory Journal Open access	25 Oct 2012	188
12	Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms Gerd Goeckenjan et al. · Pneumologie Open access	Mar 2010	166
13	Radical video-assisted mediastinoscopic lymphadenectomy (VAMLA) – technique and first results Martin Hürtgen, Godehard Friedel, H. Toomes et al. · European Journal of Cardio-Thoracic Surgery	Feb 2002	165
14	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer Gerd Goeckenjan et al. · Pneumologie Open access	14 Dec 2010	150
15	18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer Susanne Martina Eschmann, Godehard Friedel, Frank Paulsen et al. · European Journal of Nuclear Medicine and Molecular Imaging	13 Nov 2006	128
16	Leitlinie zur Spirometrie C.-P. Criée et al. · Pneumologie Open access	6 Mar 2015	120
17	Alveolar inflammation in cystic fibrosis Martina Ulrich, Dieter Worlitzsch, Simona Viglio et al. · Journal of Cystic Fibrosis Open access	30 Mar 2010	117
18	Generation and Transplantation of an Autologous Vascularized Bioartificial Human Tissue Heike Mertsching, Johanna Schanz, Volker Steger et al. · Transplantation	16 Jul 2009	114
19	Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study Caroline Deppisch, Gloria Herrmann, Ute Graepler-Mainka et al. · Infection	9 Feb 2016	113
20	Video-Assisted Mediastinoscopic Surgery: Clinical Feasibility and Accuracy of Mediastinal Lymph Node Staging Biruta Witte, Michael Wolf, Martin Huertgen et al. · The Annals of Thoracic Surgery Open access	24 Oct 2006	102
21	Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer Anna Christina Pfannenberg, Philip Aschoff, Klaus Brechtel et al. · European Journal of Nuclear Medicine and Molecular Imaging	Aug 2006	97
22	Engineered Liver-Like Tissue on a Capillarized Matrix for Applied Research Kirstin Linke, Johanna Schanz, Jan Hansmann et al. · Tissue Engineering	15 Sep 2007	94
23	Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer Julien Mazières, Dariusz Mirosław Kowalski, Alexander Valerievich Luft et al. · Journal of Clinical Oncology Open access	21 Nov 2019	92
24	Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? S. M. Eschmann, Godehard Friedel, Frank Paulsen et al. · European Journal of Nuclear Medicine and Molecular Imaging	3 Nov 2005	92
25	Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) Markus Joerger et al. · Annals of Oncology Open access	9 Aug 2016	90
26	Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer Susanne Martina Eschmann, Godehard Friedel, Frank Paulsen et al. · Lung Cancer	29 Nov 2006	85
27	Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts Silke Haubeiß, Jens O. Schmid, Thomas E. Mürdter et al. · Molecular Cancer Open access	27 Jun 2010	83
28	Resection of pulmonary metastases from renal cell carcinoma. Godehard Friedel, Martin Hürtgen, M Penzenstadler et al. · PubMed	29 Jun 1999	80
29	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier et al. · Journal of Thoracic Oncology Open access	14 Oct 2019	79
30	Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours KariT. Kivist�, Ernst‐Ulrich Griese, Péter Fritz et al. · Naunyn-Schmiedeberg s Archives of Pharmacology	1996	74
31	FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy Susanne Martina Eschmann, Godehard Friedel, Frank Paulsen et al. · European Journal of Nuclear Medicine and Molecular Imaging	5 Apr 2002	71
32	BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs Gerd K. Döring, Alessandra Bragonzi, Moira Paroni et al. · Journal of Cystic Fibrosis Open access	31 Oct 2013	70
33	A Tuft Cell–Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes Yosuke Yamada, Katja Simon‐Keller, Djeda Belharazem-Vitacolonnna et al. · Journal of Thoracic Oncology Open access	18 Feb 2021	67
34	Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis Francesco Bonella, Michael Kreuter, Lars Hagmeyer et al. · Respiration Open access	2016	67
35	Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation Sebastian P. Haen, Cécile Gouttefangeas, Diethard Schmidt et al. · Cell Stress and Chaperones Open access	25 Mar 2011	66
36	Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast Maike Sonnenberg, Heiko van der Kuip, Silke Haubeiß et al. · BMC Cancer Open access	Dec 2008	66
37	Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer Martin Weinmann, Branislav M. Jeremic, H. Toomes et al. · Lung Cancer	Mar 2003	62
38	Who Gains Most? A 10-Year Experience With 611 Thoracoscopic Talc Pleurodeses Volker Steger, Ute Mika, H. Toomes et al. · The Annals of Thoracic Surgery	26 May 2007	62
39	Sniffer dogs as part of a bimodal bionic research approach to develop a lung cancer screening E. Boedeker, Godehard Friedel, Thorsten Walles · Interactive Cardiovascular and Thoracic Surgery Open access	17 Feb 2012	60
40	The European Society of Thoracic Surgeons Lung Metastasectomy Project Dirk E. Van Raemdonck, Godehard Friedel · Journal of Thoracic Oncology Open access	20 May 2010	59
41	IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC Federico Cappuzzo, Michael McCleod, Maen Hussein et al. · Annals of Oncology Open access	Oct 2018	58
42	Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial Inga Jarosch, Tessa Schneeberger, Rainer Gloeckl et al. · Journal of Clinical Medicine Open access	21 May 2020	55
43	Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue Kari T Kivist, HeyoK. Kroemer, Péter Fritz et al. · Histochemistry and Cell Biology	1995	55
44	The Significance of Prognostic Factors for the Resection of Pulmonary Metastases of Breast Cancer Godehard Friedel, Anna Linder, H. Toomes · The Thoracic and Cardiovascular Surgeon	Apr 1994	53
45	Nightmares and oxygen desaturations: is sleep apnea related to heightened nightmare frequency? Michael Schredl, Judith Schmitt, Gerhard Hein et al. · Sleep And Breathing	23 Oct 2006	52
46	The Toxic Effects of Cigarette Additives. Philip Morris' Project Mix Reconsidered: An Analysis of Documents Released through Litigation Marcia Stanley Wertz, Thomas Kyriss, Suman Paranjape et al. · PLoS Medicine Open access	20 Dec 2011	51
47	Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study Tobias Veit, Michaela Barnikel, Alexander Crispin et al. · Respiratory Research Open access	19 Oct 2020	49
48	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry Harald M. Kaemmerer et al. · Journal of Clinical Medicine Open access	13 May 2020	49
49	Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial Maja Guberina, Wilfried Eberhardt, Martin Stuschke et al. · Annals of Oncology Open access	17 Feb 2017	49
50	Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity Dieter Munker, Tobias Veit, Jürgen Barton et al. · Infection Open access	28 Jul 2021	48

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.